PMC:7283670 / 92223-93128 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T493","span":{"begin":47,"end":55},"obj":"Disease"},{"id":"T494","span":{"begin":118,"end":125},"obj":"Disease"},{"id":"T495","span":{"begin":460,"end":468},"obj":"Disease"},{"id":"T496","span":{"begin":469,"end":479},"obj":"Disease"},{"id":"T497","span":{"begin":537,"end":545},"obj":"Disease"},{"id":"T498","span":{"begin":559,"end":567},"obj":"Disease"},{"id":"T499","span":{"begin":601,"end":609},"obj":"Disease"},{"id":"T500","span":{"begin":749,"end":757},"obj":"Disease"}],"attributes":[{"id":"A493","pred":"mondo_id","subj":"T493","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A494","pred":"mondo_id","subj":"T494","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A495","pred":"mondo_id","subj":"T495","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A496","pred":"mondo_id","subj":"T496","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A497","pred":"mondo_id","subj":"T497","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A498","pred":"mondo_id","subj":"T498","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A499","pred":"mondo_id","subj":"T499","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A500","pred":"mondo_id","subj":"T500","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T776","span":{"begin":239,"end":240},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T391","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"T392","span":{"begin":90,"end":101},"obj":"Chemical"},{"id":"T393","span":{"begin":103,"end":107},"obj":"Chemical"},{"id":"T394","span":{"begin":226,"end":237},"obj":"Chemical"},{"id":"T395","span":{"begin":263,"end":267},"obj":"Chemical"},{"id":"T396","span":{"begin":304,"end":315},"obj":"Chemical"},{"id":"T397","span":{"begin":316,"end":330},"obj":"Chemical"},{"id":"T398","span":{"begin":316,"end":325},"obj":"Chemical"},{"id":"T402","span":{"begin":326,"end":330},"obj":"Chemical"},{"id":"T404","span":{"begin":759,"end":762},"obj":"Chemical"}],"attributes":[{"id":"A391","pred":"chebi_id","subj":"T391","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A392","pred":"chebi_id","subj":"T392","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A393","pred":"chebi_id","subj":"T393","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A394","pred":"chebi_id","subj":"T394","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A395","pred":"chebi_id","subj":"T395","obj":"http://purl.obolibrary.org/obo/CHEBI_22695"},{"id":"A396","pred":"chebi_id","subj":"T396","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A397","pred":"chebi_id","subj":"T397","obj":"http://purl.obolibrary.org/obo/CHEBI_37853"},{"id":"A398","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_18367"},{"id":"A399","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_26020"},{"id":"A400","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_35780"},{"id":"A401","pred":"chebi_id","subj":"T398","obj":"http://purl.obolibrary.org/obo/CHEBI_43474"},{"id":"A402","pred":"chebi_id","subj":"T402","obj":"http://purl.obolibrary.org/obo/CHEBI_24866"},{"id":"A403","pred":"chebi_id","subj":"T402","obj":"http://purl.obolibrary.org/obo/CHEBI_26710"},{"id":"A404","pred":"chebi_id","subj":"T404","obj":"http://purl.obolibrary.org/obo/CHEBI_35640"}],"text":"Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022"}

{"project":"LitCovid-sentences","denotations":[{"id":"T795","span":{"begin":0,"end":238},"obj":"Sentence"},{"id":"T796","span":{"begin":239,"end":358},"obj":"Sentence"},{"id":"T797","span":{"begin":359,"end":437},"obj":"Sentence"},{"id":"T798","span":{"begin":438,"end":479},"obj":"Sentence"},{"id":"T799","span":{"begin":480,"end":515},"obj":"Sentence"},{"id":"T800","span":{"begin":516,"end":784},"obj":"Sentence"},{"id":"T801","span":{"begin":785,"end":816},"obj":"Sentence"},{"id":"T802","span":{"begin":817,"end":905},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T264","span":{"begin":144,"end":165},"obj":"Phenotype"},{"id":"T265","span":{"begin":639,"end":660},"obj":"Phenotype"}],"attributes":[{"id":"A264","pred":"hp_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/HP_0002086"},{"id":"A265","pred":"hp_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/HP_0002086"}],"text":"Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1971","span":{"begin":26,"end":37},"obj":"Species"},{"id":"1972","span":{"begin":118,"end":137},"obj":"Species"}],"attributes":[{"id":"A1971","pred":"tao:has_database_id","subj":"1971","obj":"Tax:11118"},{"id":"A1972","pred":"tao:has_database_id","subj":"1972","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:\na loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months\nPlacebo comparator: placebo Not applicable Primary (approximately 100 days):\nNumber of symptomatic COVID‐19 infections\nSecondary (approximately 100 days):\nSymptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity\nOther (approximately 100 days):\nDrug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022"}